Bull case
iBio is attractive fundamentally because IBIO-610 has unusually strong and internally consistent preclinical evidence, including up to 98% Activin E suppression at 8 weeks, a 33.2-day NHP half-life, and a projected human half-life of approximately 100 days, which supports a durable, infrequently dosed obesity and cardiometabolic therapy. The thesis is further strengthened by body-composition data showing reduced visceral and total fat with lean-mass preservation, plus combination benefits with semaglutide that address a major market gap in maintenance after GLP-1 discontinuation. The broader pipeline also adds value through IBIO-600 and IBIO-800, while current comparison to competitor mechanisms and a current enterprise value below the cited $950M mechanism-validation transaction suggest meaningful upside from platform breadth and target de-risking.